Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Katy Dodt

Nurse Practitioner, Primary Care Queen Creek, AZ Nurse Practitioner

NPI 1710609128 CMS profile 11405472

21321 E Ocotillo Rd, Queen Creek, AZ 85142

Open in the dashboard

General payments

$4,903

262 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katy Dodt of Queen Creek, AZ is reported in the CMS Open Payments database as having received $4,903 across 262 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,820 95
2024 General $1,887 102
2023 General $1,072 58
2022 General $123 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katy Dodt
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Katy Dodt were reported at $1,820. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Katy Dodt Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $123 $139 $44–$421 $149
2023 $1,072 $163 $53–$481 $160
2024 $1,887 $176 $54–$511 $164
2025 $1,820 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,247 87 payments
  2. AstraZeneca Pharmaceuticals LP $664 11 payments
  3. Novo Nordisk Inc $409 22 payments
  4. Lilly USA, LLC $360 23 payments
  5. Pfizer Inc. $306 22 payments
  6. GlaxoSmithKline, LLC. $240 13 payments
  7. ITI, Inc. $227 8 payments
  8. Amgen Inc. $219 16 payments
  9. Astellas Pharma US Inc $192 8 payments
  10. Janssen Pharmaceuticals, Inc $104 5 payments
  11. Other $934 47 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,846 260 payments
  2. Education $57 2 payments
Products named General payments · program years 2022–2025
  1. QULIPTA $582 34 payments
  2. AIRSUPRA $508 5 payments
  3. VRAYLAR $488 37 payments
  4. UBRELVY $375 24 payments
  5. FARXIGA $328 3 payments
  6. MOUNJARO $319 19 payments
  7. BREZTRI $299 5 payments
  8. Ozempic $231 12 payments
  9. NURTEC ODT $213 16 payments
  10. CAPLYTA $207 7 payments
  11. Other $3,419 202 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

1,185

Median for Nurse Practitioner: 389

Drug cost

$106,717

Median for Nurse Practitioner: $21,885

Branded share of claims

24%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 40 $43,599
Ozempic Semaglutide Brand 37 $40,889
Eliquis Apixaban Brand 17 $10,485
Gabapentin Generic 62 $1,245
Albuterol Sulfate Hfa Albuterol Sulfate Brand 51 $1,098
Lisinopril Generic 76 $587
Metformin Hcl Generic 50 $558
Atorvastatin Calcium Generic 65 $553
Omeprazole Generic 34 $512
Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide Brand 27 $497

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$88,053

Of which drugs: $2,819

Medicare patients

210

Average age 73

Services billed

2,064

137 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 44%
Chronic kidney disease 43%
Ischemic heart disease 26%
Depression 26%
Diabetes 21%
Osteoporosis 17%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 16 16 $1,309

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $199
$199 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $179
$179 — —
QULIPTA
  • AbbVie, Inc. $159
$159 — —
MOUNJARO
  • Lilly USA, LLC $132
$132 40 —
Repatha
  • Amgen Inc. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

262 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record